Ironwood Pharmaceuticals (IRWD) investor relations material

Strategic and financial outlook

• Anticipates a turnaround year with a projected $300 million swing in net sales growth, driven by a bold WAC pricing strategy and continued LINZESS expansion.

• Plans to pay off $200 million in convertible notes this month, aiming to end the year with $300 million in debt, aligning with EBITDA.

• Focused on maximizing LINZESS value, accelerating apraglutide clinical development, and maintaining strong free cash flow for debt reduction.

• Interim CFO in place after recent departure, with no disruption expected in financial management.

Apraglutide clinical and market development

• Initiating a smaller, shorter confirmatory trial for apraglutide this month, following positive phase III data in SBS-IF.

• Differentiated by once-weekly dosing, strong tolerability, and potential for enteral autonomy; long-term extension data show increasing benefit over time.

• Exploring additional indications beyond SBS-IF, such as IBD, but primary focus remains rapid enrollment in the confirmatory trial.

• Confident in replicating prior efficacy and safety results; considering dose escalation studies for partial responders.

• Market research suggests apraglutide could achieve class-leading share despite anticipated generic and competitor entries.

Competitive landscape and differentiation

• GLP-2 mechanism gaining industry interest, with recent deals highlighting platform potential beyond SBS.

• Apraglutide seen as ahead of competitors due to advanced clinical data and favorable tolerability profile.

• Differentiation from GATTEX and generics centers on improved adherence, tolerability, and once-weekly administration.

• U.S. generic entry expected in 2026–2027, but multi-source generics unlikely due to complex patient management needs.